MicuRx Announces CARB-X US$7.78 Million Funding for Development of MRX-8
08/13/20, 12:21 PM
Location
foster cityMoney raised
$7 million
MicuRx Pharmaceuticals Inc. today announced that the global partnership Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has committed up to US$7.78 million of nondilutive financing for a Phase 1 clinical trial and related R&D activities of its new antimicrobial agent MRX-8. Previously, CARB-X has funded investigational new drug (IND) enabling studies for MRX-8 in the US.
Company Info
Location
foster city, california, united states
Additional Info
MicuRx is a privately held biopharmaceutical company focusing on discovering and developing antibiotics with improved safety profiles to treat resistant bacterial infections. The lead compound, contezolid, a next-generation oxazolidinone targeting methicillin-resistant S. aureus, was structure-designed to reduce hematological adverse effects of this antibiotic class. MicuRx completed two Phase 2 studies in the US and China for contezolid. After completing a successful Phase 3 study in China for the treatment of complicated skin and soft tissue infections, the company filed an NDA with the NMPA of China for contezolid at the end of 2019. The company has research and development facilities outside San Francisco, CA, in the United States, and in Shanghai, China. Visit www.micurx.com for more information.